Wednesday, April 8, 2009

Psoriasis Drug Pulled From Market

WEBMD NEWS ALERT
Wednesday, April 8, 2009

Psoriasis Drug
Pulled From Market
http://health.webmd.com/cgi-bin21/DM/y/e6dZ0Nec4j0LOZ0BgzN0E4
Drugmaker Genentech is pulling their psoriasis drug Raptiva from the market because of the risk of developing PML, a potentially fatal brain infection.
> More on Raptiva's Withdrawal
http://health.webmd.com/cgi-bin21/DM/y/e6dZ0Nec4j0LOZ0BgzN0E4

Related News & Resources
> Get Details on PML (Progressive Multifocal Leukoencephalopathy)
http://health.webmd.com/cgi-bin21/DM/y/e6dZ0Nec4j0LOZ0BgzO0E5
> Psoriasis Drug Raptiva Tied to Brain Infection
http://health.webmd.com/cgi-bin21/DM/y/e6dZ0Nec4j0LOZ0BgzP0E6
> Raptiva Gets FDA Black Box Warning
http://health.webmd.com/cgi-bin21/DM/y/e6dZ0Nec4j0LOZ0BgzQ0E7
> Understanding Psoriasis
http://health.webmd.com/cgi-bin21/DM/y/e6dZ0Nec4j0LOZ0BgzR0E8
> See Pictures for a Closer Look at Psoriasis
http://health.webmd.com/cgi-bin21/DM/y/e6dZ0Nec4j0LOZ0BgzS0EA

WebMD Shortcuts
*****************************************************************
> Home Page
http://health.webmd.com/cgi-bin21/DM/y/e6dZ0Nec4j0LOZ0BgzT0EB
> News Center
http://health.webmd.com/cgi-bin21/DM/y/e6dZ0Nec4j0LOZ0BgzU0EC
> Health Topics
http://health.webmd.com/cgi-bin21/DM/y/e6dZ0Nec4j0LOZ0BgzV0ED
> Expert Blogs & Boards
http://health.webmd.com/cgi-bin21/DM/y/e6dZ0Nec4j0LOZ0BgzW0EE

You are subscribed as healthysmile4u@gmail.com.
> View and manage your WebMD newsletter preferences
http://health.webmd.com/cgi-bin21/DM/y/e6dZ0Nec4j0LOZ0xA20Ep&e=aGVhbHRoeXNtaWxlNHVAZ21haWwuY29t
> Subscribe to more newsletters here.
http://health.webmd.com/cgi-bin21/DM/y/e6dZ0Nec4j0LOZ0xA20Ep&e=aGVhbHRoeXNtaWxlNHVAZ21haWwuY29t
> Change/update your email address.
http://health.webmd.com/cgi-bin21/DM/y/e6dZ0Nec4j0LOZ0xA20Ep&e=aGVhbHRoeXNtaWxlNHVAZ21haWwuY29t

WebMD Privacy Policy
http://health.webmd.com/cgi-bin21/DM/y/e6dZ0Nec4j0LOZ0BgzX0EF
WebMD Office of Privacy
1175 Peachtree Street, Suite 2400, Atlanta, GA 30361
(c) 2009 WebMD, LLC. All rights reserved.

No comments: